Correlation of HLA-Cw6 Positivity with Clinical Characteristics and Treatment Efficacy in Korean Patients with Psoriasis
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background: Psoriasis is a multifactorial, chronic immunological disease, in which a specific allele HLA-Cw6 is associated with various clinical manifestations. However, information re- garding this genetic factor in Korean patients with psoriasis remains limited. Objective: We aimed to explore the differences in clinical patterns and treatment respon- siveness, depending on the expression of HLA-Cw6, in Korean patients with psoriasis. Methods: We divided patients into two groups, namely HLA-Cw6-positive and HLA- Cw6-negative, based on the HLA-Cw6 allelic analysis using the single specific primer- polymerase chain reaction method. All clinical information regarding these patients was collected in a retrospective manner. Next, we evaluated the levels of serum Th17-related cytokines in 34 patients diagnosed with psoriasis using a multiplex immunoassay. Finally, we performed immunohistochemical staining of interleukin (IL)-22 and IL-31, as these cytokines showed the maximum differential expression between the HLA-Cw6 positive and negative groups. Results: HLA-Cw6 positive and negative groups comprised of 13 and 21 patients, respec- tively. HLA-Cw6-positive group had more chance of having metabolic comorbidities (76.9% for HLA-Cw6-positive group; 28.6% for HLA-Cw6-negative group; =0.002). Also, HLA-Cw6-positive group showed significantly higher treatment response (38.5% in posi- tive group showed Psoriasis Area and Severity Index 90% improvement compared to 4.8% in the negative group; =0.012). However, all Th17-related cytokines were not significantly different across the two groups. Furthermore, IL-22 and IL-31 immunohistochemical staining did not correlate with the serum cytokines levels. Conclusion: HLA-Cw6 types can be associated with disease severity, comorbidities, and treatment responsiveness in Korean patients with psoriasis.
Abstract
Background: Psoriasis is a multifactorial, chronic immunological disease, in which a specific allele HLA-Cw6 is associated with various clinical manifestations. However, information re- garding this genetic factor in Korean patients with psoriasis remains limited. Objective: We aimed to explore the differences in clinical patterns and treatment respon- siveness, depending on the expression of HLA-Cw6, in Korean patients with psoriasis. Methods: We divided patients into two groups, namely HLA-Cw6-positive and HLA- Cw6-negative, based on the HLA-Cw6 allelic analysis using the single specific primer- polymerase chain reaction method. All clinical information regarding these patients was collected in a retrospective manner. Next, we evaluated the levels of serum Th17-related cytokines in 34 patients diagnosed with psoriasis using a multiplex immunoassay. Finally, we performed immunohistochemical staining of interleukin (IL)-22 and IL-31, as these cytokines showed the maximum differential expression between the HLA-Cw6 positive and negative groups. Results: HLA-Cw6 positive and negative groups comprised of 13 and 21 patients, respec- tively. HLA-Cw6-positive group had more chance of having metabolic comorbidities (76.9% for HLA-Cw6-positive group; 28.6% for HLA-Cw6-negative group; =0.002). Also, HLA-Cw6-positive group showed significantly higher treatment response (38.5% in posi- tive group showed Psoriasis Area and Severity Index 90% improvement compared to 4.8% in the negative group; =0.012). However, all Th17-related cytokines were not significantly different across the two groups. Furthermore, IL-22 and IL-31 immunohistochemical staining did not correlate with the serum cytokines levels. Conclusion: HLA-Cw6 types can be associated with disease severity, comorbidities, and treatment responsiveness in Korean patients with psoriasis.
참고문헌 (25)
- Armstrong AW, "Psoriasis and metabolic syndrome : a systematic review and meta-analysis of observational studies", J Am Acad Dermatol, 68, pp.654~662 (2013)
- Mehta NN, "Patients with severe psoriasis are at increased risk of cardiovascular mortality : cohort study using the General Practice Research Database", Eur Heart J, 31, pp.1000~1006 (2010)
- Chen L, "HLA-Cw6 and psoriasis", Br J Dermatol, 178, pp.854~862 (2018)
- Henseler T, "Psoriasis of early and late onset : characterization of two types of psoriasis vulgaris", J Am Acad Dermatol, 13, pp.450~456 (1985)
- Theodorakopoulou E, "Early-and late-onset psoriasis : a crosssectional clinical and immunocytochemical investigation", Br J Dermatol, 175, pp.1038~1044 (2016)
- Chiu HY, "Human leucocyte antigen-Cw6 as a predictor for clinical response to ustekinumab, an interleukin-12", 23 blocker, in Chinese patients with psoriasis : a retrospective analysis, 2014, pp.171, 1181~1188
- Chiu HY, "HLA polymorphism among Chinese patients with chronic plaque psoriasis : subgroup analysis", Br J Dermatol, 166, pp.288~297 (2012)
- Zhou Yi, "A Large-Scale, Stratified Genetic Analysis of the Major Histocompatibility Complex Region in Early- and Late-Onset Psoriasis in China", Annals of Dermatology, 33(1), pp.61~67 (2021), 대한피부과학회[DOI]
- Indhumathi S, "Pharmacogenetic markers to predict the clinical response to methotrexate in south Indian Tamil patients with psoriasis", Eur J Clin Pharmacol, 73, pp.965~971 (2017)
- Galluzzo M, "IL12B(p40)gene polymorphisms contribute to ustekinumab response prediction in psoriasis", Dermatology, 232, pp.230~236 (2016)
- Talamonti M, "Pharmacogenetics of psoriasis : HLA-Cw6 but not LCE3B", 3C deletion nor TNFAIP3 polymorphism predisposes to clinical response to interleukin 12, Br J Dermatol, pp.2013, 169[DOI]
- Talamonti M, "HLA-C*06 and response to ustekinumab in Caucasian patients with psoriasis : outcome and long-term follow-up", J Am Acad Dermatol, 74, pp.374~375 (2016)
- Nam SH, "Correlations between HLA-Cw*0602 and clinical picture in Korean psoriatic patients", Korean J Dermatol, 39, pp.183~189 (2001)
- Talamonti M, "Role of the HLA-C*06 allele in clinical response to ustekinumab : evidence from real life in a large cohort of European patients", Br J Dermatol, 177, pp.489~496 (2017)
- Liakou AI, "Links and risks associated with psoriasis and metabolic syndrome", Psoriasis(Auckl), 5, pp.125~128 (2015)
- Armstrong AW, "A tale of two plaques : convergent mechanisms of T-cell-mediated inf lammation in psoriasis and atherosclerosis", Exp Dermatol, 20, pp.544~549 (2011)
- Whitlock SM, "Management of psoriasis in patients with inflammatory bowel disease : from the Medical Board of the National Psoriasis Foundation", J Am Acad Dermatol, 78, pp.383~394 (2018)
- Wolk K, "IL-22 regulates the expression of genes responsible for antimicrobial defense, cellular differentiation, and mobility in keratinocytes : a potential role in psoriasis", Eur J Immunol, 36, pp.1309~1323 (2006)
- Sabat R, "Therapeutic opportunities of the IL-22-IL-22R1 system", Nat Rev Drug Discov, 13, pp.21~38 (2014)
- Zaba LC, "Amelioration of epidermal hyperplasia by TNF inhibition is associated with reduced Th17responses", J Exp Med, 205, pp.1941~ (2008)
- Shimauchi T, "Serum interleukin-22 and vascular endothelial growth factor serve as sensitive biomarkers but not as predictors of therapeutic response to biologics in patients with psoriasis", J Dermatol, 40, pp.856~ (2013)
- Gibbs BF, "Role of the pruritic cytokine IL-31 in autoimmune skin diseases", Front Immunol, 10, pp.1383~ (2019)
- Narbutt J, "Narrow band ultraviolet B irradiations cause alteration in interleukin-31 serum level in psoriatic patients", Arch Dermatol Res, 305, pp.191~195 (2013)
- Nattkemper LA, "The genetics of chronic itch : gene expression in the skin of patients with atopic dermatitis and psoriasis with severe itch", J Invest Dermatol, 138, pp.1311~1317 (2018)
- 황상현, "한국인의 HLA-A, -B, -C 대립유전자와 일배체형 분포", Annals of Laboratory Medicine, 24(6), pp.396~404 (2004), 대한진단검사의학회